Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Obexelimab - Zenas Biopharma

Next Previous
Drug Profile

Obexelimab - Zenas Biopharma

Alternative Names: AMG 729; Humanised Fc-engineered monoclonal antibody against CD19 - Xencor; XmAb® 5871

Latest Information Update: 03 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xencor
  • Developer Bristol-Myers Squibb; Xencor; Zenas BioPharma
  • Class Antianaemics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD19 antigen inhibitors; Fc gamma receptor IIB antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autoimmune disorders
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Immunoglobulin G4-related disease
  • Phase III Multiple sclerosis; Systemic lupus erythematosus
  • No development reported Autoimmune disorders
  • Discontinued Autoimmune haemolytic anaemia; Rheumatoid arthritis

Most Recent Events

  • 03 Sep 2026 Phase-III clinical trials in Systemic lupus erythematosus (unspecified route) (Xencor pipeline, September 2026)
  • 20 Aug 2026 Planned Prescription Drug User Fee Act (PDUFA) date for Immunoglobulin G4 related disease (Prevention) in USA (SC) is 2027-05-27
  • 13 Aug 2026 Preregistration for Immunoglobulin G4 related disease (Prevention) in Japan (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top